Olivier Roger Jarry - 31 Dec 2024 Form 5 Insider Report for OS Therapies Inc (OSTX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
5
Accepted by SEC
14 Feb 2025, 16:24:01 UTC
Prior SEC filing
29 Oct 2024
Next SEC filing
19 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Olivier Jarry
Filing notes and source

Key filing fact

Olivier Roger Jarry filed Form 5 for OS Therapies Inc (OSTX) on 14 Feb 2025.

Key facts

  • This page summarizes Olivier Roger Jarry's Form 5 filing for OS Therapies Inc (OSTX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 14 Feb 2025, 16:24.

Change

  • Previous filing in this sequence was filed on 29 Oct 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OSTX transaction Derivative

Non-qualified stock options (right to buy)

Award

Transaction value
$0
Shares
+40,000
Change %
Price
$0.000000
Shares after
40,000
Date
05 Dec 2024
Ownership
Direct
Underlying class
Common stock, par value $0.001 per share
Underlying amount
40,000
Exercise price
$1.86
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On December 5, 2024, the reporting person was granted non-qualified stock options to purchase 40,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and subject to certain vesting conditions.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .